Skip to main content

Monoclonal Antibodies (mAb)

Let's spread the word about Immunotherapy! Click to share this page with your community.

img_table1_Mabs.pngMonoclonal antibodies (mAbs) are specifically designed to target cancer cells

How does it work?

  • mAbs are a special type of protein designed to target antigens, or markers, located on the surface of cancer cells
  • Antibodies locate antigens and recruit immune cells to attack
  • mAbs can also interfere with cell signaling, helping to block growth and communication of tumor cells

For which cancers is it currently used or being studied?

Immunotherapy mAbs are approved by the FDA for a wide range of cancers including:

  • Breast (Herceptin®, Kadcyla®, Perjeta®) 
  • Hodgkin’s lymphoma (Adcetris®)
  • Non-Hodgkin’s lymphoma (Rituxan®, Zevalin®)
  • Colorectal (Avastin®, Erbitux®, Vectibix®)
  • Lung (Avastin®, Cyramza®)
  • Chronic lymphocytic leukemia (Gazyva®, Campath®, Rituxan®, Arzerra®)
  • Gastric (Herceptin®, Cyramza®)
  • Kidney (Avastin®)
  • Brain (Avastin®)
  • Cervical (Avastin®)
  • Ovarian (Avastin®)
  • Acute lymphoblastic leukemia (Blincyto®)

Several mAbs are currently in clinical trials for a wide variety of cancer types:

  • Bavituximab (breast, liver, lung, melanoma, pancreatic, rectal)
  • Ch14.18 (neuroblastoma)
  • Rilotumumab (fallopian, gastric, ovarian)

*Immunotherapy results may vary from patient to patient.